The global atherosclerosis drugs market is expected to grow at a significant CAGR during the forecast period (2021-2027). The rise in the prevalence of atherosclerosis and cardiovascular disorders is a major factor driving the market’s growth. According to the European Heart Network, cardiovascular disease kills 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union. In wealthy countries, sedentary lifestyles are responsible for the highest rates of cardiovascular disease. Sedentary behaviour is associated with a high prevalence of high blood pressure, high cholesterol, obesity, and excessive alcohol intake, all of which contribute to an increased risk of cardiovascular disease. As a result, the market examined is predicted to be driven by a sedentary lifestyle resulting in a high prevalence of cardiovascular illnesses and rising awareness of treatment choices.

Statins and fibrates are two types of cholesterol-lowering medicines. The growing prevalence of cardiovascular disease, high cholesterol, and obesity globally is responsible for the segment's dominance. In 2018, the World Health Organization (WHO) predicted that 40 million children under the age of five were overweight or obese. Increased consumption of high-fat, high-sugar foods, as well as an increase in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization, are all contributing to high cholesterol rates and, as a result, segment growth.

In addition, the approval of new cholesterol-lowering medications is boosting the market growth. For instance, the pharmaceuticals alirocumab (Praluent) and evolocumab (Repatha) are part of a novel class of treatments known as PCSK9 inhibitors, which reduce dangerous LDL cholesterol levels by more than 50%. Novel therapeutic medications like this help to drive segment growth. The segment's growth is aided by an expanding patient pool and increased approvals of new medications.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Pfizer Inc., AstraZeneca, Merck & Co., Inc., Sanofi US, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Atherosclerosis Drugs Market by Segments

By Drug Class

• Anti-Platelet Medications

• Cholesterol-Lowering Medications

• Fibric Acid and Omega-3 Fatty Acid Derivatives

• Beta Blockers

• Others 

By Distribution Channel 

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy 

Global Atherosclerosis Drugs Market by Region